HIV-1 inhibitor-66

Cat. No.:	HY-162461
Molecular Formula:	$C_{22}H_{15}BrClF_3N_4O_3$
Molecular Weight:	555.73
Target:	Reverse Transcriptase; HIV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	HIV-1 inhibitor-66 is an orally active non-nucleoside reverse transcription inhibitor (NNRTI). HIV-1 inhibitor-66 shows inhibitory activity against wild-type HIV-1 reverse transcriptase with an IC_{50} of 40 nM[1].
In Vitro	HIV-1 inhibitor-66 (compound 10n) inhibits wild-type (WT) HIV-1 (IIIB) and NNRTIs-resistant strains, with EC_{50} values of 0.009 μM, 0.011 μM, 0.013 μM, 0.018 μM, 0.703 μM, 0.013 μM,17.7 μM, and 0.059 μM against HIV-1 IIIB, L100I, K103N, Y181C, Y188L, E138 K, F227L/V106A, and RES056 (K103N/Y181C), respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	HIV-1 inhibitor-66 (compound 10n) demonstrates excellent pharmacokinetic profile ($T_{1/2}$=5.09 h, F=108.96%) in rats. HIV-1 inhibitor-66 is verified to have no in vivo acute or subacute toxicity (LD50>2000 mg/kg)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Yanying Sun, et al. Discovery of Novel Aryl Triazolone Dihydropyridines (ATDPs) Targeting Highly Conserved Residue W229 as Promising HIV-1 NNRTIs. J Med Chem. 2024 Apr 25;67(8):6570-6584.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA